Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism
Advanced Science · 2024-08 · 11 (31)
DOI: 10.1002/advs.202400493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 18.06.2024. Verfasst von Yu Bai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, P. R.…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Glycerophospholipids, Nanoparticles, CRISPR-Cas Systems. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Non‐alcoholic fatty liver disease (NAFLD) is a prominent cause of various chronic metabolic hepatic diseases with limited therapeutics. Rubicon, an essential regulator in lysosomal degradation, is reported to exacerbate hepatic steatosis in NAFLD mice and patients, indicating its probability of being a therapeutic target for NAFLD treatment. In this study, the therapeutic potential of Rubicon blockage is investigated. Lipid nanoparticles carrying Rubicon‐specific CRISPR‐Cas9 components exhibited liver accumulation, cell internalization, and Rubicon knockdown. A single administration of the nanoparticles results in attenuated lipid deposition and hepatic steatosis, with lower circulating lipid levels and decreased adipocyte size in NAFLD mice. Furthermore, the increase of phosphatidylcholine and phosphatidylethanolamine levels can be observed in the NAFLD mice livers after Rubicon silencing, along with regulatory effects on metabolism‐related genes such as CD36, Gpcpd1, Chka, and Lpin2. The results indicate that knockdown of Rubicon improves glycerophospholipid metabolism and thereby ameliorates the NAFLD progression, which provides a potential strategy for NAFLD therapy via the restoration of Rubicon.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, P. R. China.
- Department of Research and Development, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, P. R. China.
- Fudan Zhangjiang Institute, Shanghai, 201203, P. R. China.
- Shanghai Hailu Biological Technology Co., Ltd., Shanghai, 201200, P. R. China.
ORCID-Profile: Dianwen Ju
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
- Shanghai Science and Technology Development Foundation
Zitieren
APA
Bai, Y., Nan, Y., Wu, T., Zhu, A., Xie, X., Sun, Y., Deng, Y., Dou, Z., Hu, X., Zhou, R., Xu, S., Zhang, Y., Fan, J., & Ju, D. (2024). Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism. Advanced Science, 11(31). https://doi.org/10.1002/advs.202400493
Vancouver
Bai Y, Nan Y, Wu T, Zhu A, Xie X, Sun Y, et al. Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism. Advanced Science. 2024;11(31). doi:10.1002/advs.202400493
BibTeX
@article{Bai2024,
author = {Bai, Yu and Nan, Yanyang and Wu, Tao and Zhu, An and Xie, Xinlei and Sun, Yun and Deng, Yong and Dou, Zihan and Hu, Xiaozhi and Zhou, Rongrui and Xu, Shuwen and Zhang, Yuanzhen and Fan, Jiajun and Ju, Dianwen},
title = {Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {31},
doi = {10.1002/advs.202400493}
}
EUVIMED